ASX Announcement PERCHERON AND INVION TO EXPLORE NOVEL COMBINATION OF VISTA IMMUNOTHERAPY AND PHOTOSOFT™ FOR CANCER • Percheron Therapeutics and Invion to undertake preclinical studies evaluating HMBD-002, a VISTA targeting immune checkpoint inhibitor (ICI), in combination with Invion’s...
PER: Percheron and Invion Explore Cancer Combination Therapy
Filed with ASX ·
6ix hasn’t read this filing yet.
Percheron Therapeutics Limited on 6ix
Earlier from Percheron Therapeutics
- Change of Director's Interest Notice
- Notice under S708A
- Application for quotation of securities - PER
- Notification regarding unquoted securities - PER
- Results of Annual General Meeting
Later from Percheron Therapeutics
- Photosoft & Novel Immunotherapy Collab Partnership
- Quarterly Activities Report and Appendix 4C
- Completion of HMBD-002 Drug Product Manufacture
- Listing Rule waiver to allow quotation of PERAQ options
- FDA Clearance for Vanderbilt Health Clinical Trial in AML
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics